Bausch Health's Aplenzin could revolutionize TRD care, addressing a $3B market opportunity while aiding BHC stock's financial ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective lowered by stock analysts at Stifel Nicolaus from $17.00 ...

NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

President Trump’s tariffs will hit pacemakers, X-ray machines and other medical devices manufactured overseas and shipped to ...

Bausch + Lomb Co. (NYSE:BLCO – Get Free Report)’s stock price reached a new 52-week low during trading on Thursday after ...

The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...

NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Miebo produced substantial symptom relief in patients with dry eye disease during the first day and succeeding weeks of ...

It is important, stresses Scott, to foster a dialogue between past historic works and present new works. Moreover, she adds, Dance Reflections is “magnifying,” the number of dance companies, dancers ...

Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome ...

Detailed price information for Bausch Health Companies Inc (BHC-T) from The Globe and Mail including charting and trades.